2023-02-09: Semaglutide weight-loss drugs Ozempic and Wegovy show 15% non-responders with less than 5% body weight loss.

2023-02-09: Ozempic and Wegovy, weight-loss drugs containing semaglutide, have been gaining popularity, with over nine million prescriptions written in the US in the last three months of 2022. However, some users may not see significant weight loss, with up to 15% of patients considered 'non-responders' - those who lose less than 5% of their body weight. Researchers continue to study the factors behind the variation in weight loss experienced by patients.

April 01, 2024
6 Articles

Further Reading